Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 30, 2016 - Issue 24
178
Views
3
CrossRef citations to date
0
Altmetric
Short Communications

Prisconnatanones A, a cytotoxic naphthoquinone from Prismatomeris connata, suppresses the proliferation of human laryngocarcinoma HEp-2 cells in vitro

, , &
Pages 2840-2844 | Received 14 Jul 2015, Accepted 16 Feb 2016, Published online: 16 Mar 2016
 

Abstract

Prisconnatanones A (Priscon-A) is a rare tetrahydroanthraquinone isolated from herbal Prismatomeris connate. In this study, we examine its anti-tumour activity on human laryngocarcinoma HEp-2 cells in vitro. The CCK-8 assay was performed to evaluate its cytotoxicity. Cell cycle and apoptosis were analysed using flow cytometric analysis. Here, we showed Priscon-A inhibited the proliferation of HEp-2 cells in a dose-dependent manner, and at 5 μM it almost completely inhibited cell growth. Its cytotoxicity was associated with the cell cycle arrest at G2/M phase. The Annexin V-FITC/PI binding assay showed that the cell death induced by Priscon-A was associated with apoptosis. And, western blot analysis revealed that the levels of the apoptosis protein, cleaved caspase-3, PARP, p21 and Bax protein increased, while the level of anti-apoptosis protein Bcl-2 decreased.. These data demonstrated that Priscon-A significantly inhibited HEp-2 cell growth, induced the cell cycle arrest at the G2/M phase and efficiently induced cell apoptosis.

Prisconnatanones A, a cytotoxic naphthoquinone from Prismatomerisconnata, suppresses the proliferation of human laryngocarcinoma HEp-2 cells in vitro

Funding

This work was supported by Science and Technology Project for Fundamental Research of Shenzhen [grant number JCYJ20140905095624296]; National Natural Science Foundation of China [grant number 31500284]; the Shenzhen Urban Management Bureau Grant [grant number 201416].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.